Health
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate – BioSpace
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19…
Sanofi and GSK initiateglobal Phase 3clinical efficacy study of COVID-19 vaccinecandidate
- Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants
- A booster study program will begin in the coming weeks to complement Phase 3 trial
- Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment…
Continue Reading
-
Business19 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business21 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business18 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
General10 hours agoVictorian school teacher charged with soliciting child abuse material